SCHEMBL3207580

SCHEMBL3207580

O=S(=O)(c1ccc2c(Cl)cccc2c1)N1CCN(c2ccc(F)cc2C(F)(F)F)CC1

nearest known ligand 0.72

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 15/20 0.72
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
RECQL P46063 1/20 0.47
LMNA P02545 2/20 0.46
TP53 P04637 1/20 0.46
GAA P10253 1/20 0.46
HTT P42858 1/20 0.46
GBA1 P04062 1/20 0.46
POLB P06746 1/20 0.45
MAPT P10636 1/20 0.45
GFER P55789 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3209913 0.86 HSD11B1 (0.72) HSD11B1MEN1KMT2ASMN1; SMN2RECQL
SCHEMBL4486893 0.84 HSD11B1 (1.00) HSD11B1MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL3213328 0.82 HSD11B1 (0.80) HSD11B1SMN1; SMN2LMNATP53GAA
SCHEMBL3201753 0.81 ALDH1A1 (0.51) MEN1KMT2ASMN1; SMN2LMNAGAA
SCHEMBL13489671 0.80 HSD11B1 (0.69) HSD11B1MEN1KMT2AGFER
SCHEMBL3210235 0.79 HSD11B1 (0.68) HSD11B1MEN1KMT2A
SCHEMBL3222991 0.78 HSD11B1 (0.72) HSD11B1HTT
SCHEMBL3223548 0.77 HSD11B1 (0.72) HSD11B1HTT
SCHEMBL3214960 0.76 HSD11B1 (0.73) HSD11B1HTT
SCHEMBL3213320 0.75 HSD11B1 (0.75) HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029648-A1 11-Beta HSD1 Inhibitors XIANG JASON SHAOYUN 2010-02-04 US disclosed
US-7632838-B2 11-beta HSD1 inhibitors WYETH (US) 2009-12-15 US disclosed
EP-1981848-A2 11-BETA HSD1 INHIBITORS Wyeth (US) 2008-10-22 EP disclosed
US-20070219198-A1 11-Beta HSD 1 inhibitors WYETH (US) 2007-09-20 US disclosed
WO-2007092435-A2 11-BETA HSD1 INHIBITORS WYETH (US) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029648-A1 11-Beta HSD1 Inhibitors HSD11B1, HSD3B1, HSD11B2 HSD11B1 1/4885MEN1 1354/4885KMT2A 1609/4885
US-20070219198-A1 11-Beta HSD 1 inhibitors HSD11B1, HSD11B2, HSD3B1 HSD11B1 1/4885MEN1 1687/4885KMT2A 1591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.